SUDEEP PHARMA Latest Share Price (SUDEEPPHRM)
TODAY IN ONE LINE
SUDEEPPHRM is little changed at ₹1003.30 — a quiet consolidation day.
With a market cap of ₹11,289.22 Cr., it trades at a P/E of 61.74. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
SUDEEP PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 17.7% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 19.4%
- ●Healthy Operating MarginsOPM is structurally strong at 36.7%
- ●High Promoter HoldingPromoters hold 76.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.17x
- ●FII AccumulationFII holding increased by 1.12% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 55.1x
Latest SUDEEP PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
SUDEEP PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for SUDEEP PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
SUDEEP PHARMA trades at a P/E of 61.74× and P/B of 12.78×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
SUDEEP PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SUDEEP PHARMA — derived from the latest tape, not yesterday's close.
SUDEEP PHARMA last traded at ₹1,003.3 with an intraday range of ₹964.7–₹1,016.8 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1003.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1129.37 | +126.07 | +12.57% |
| R3 | 1077.27 | +73.97 | +7.37% |
| R2 | 1047.03 | +43.73 | +4.36% |
| R1 | 1025.17 | +21.87 | +2.18% |
| PIVOT | 994.93 | -8.37 | -0.83% |
| CURRENT | 1003.30 | — | — |
| S1 | 973.07 | -30.23 | -3.01% |
| S2 | 942.83 | -60.47 | -6.03% |
| S3 | 920.97 | -82.33 | -8.21% |
| S4 | 868.87 | -134.43 | -13.40% |
SUDEEPPHRM is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹977.2–₹1000
Trading Inside opening range
SUDEEP PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for SUDEEP PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
SUDEEP PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹11,289.22 Cr. and reported EPS of ₹3.59.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 642 | 642 ▲ 0.0% |
| Other Income | 29 | 29 ▲ 0.0% |
| Total Income | 671 | 671 ▲ 0.0% |
| 227 | 227 ▲ 0.0% | |
| Gross ProfitDerived | 415 | 415 ▲ 0.0% |
| Gross Margin %Derived | 64.61% | 64.61% |
| 193 | 193 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 222 | 222 ▲ 0.0% |
| OPM %Derived | 34.55% | 34.55% |
| 22 | 22 ▲ 0.0% | |
| Profit Before Tax (PBT) | 228 | 228 ▲ 0.0% |
| 54 | 54 ▲ 0.0% | |
| Effective Tax %Derived | 23.58% | 23.58% |
| Total Profit for Period | 174 | 174 ▲ 0.0% |
| Less: Non-controlling Interests | 1 | 1 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 173 | 173 ▲ 0.0% |
| Net Profit Margin %Derived | 26.92% | 26.92% |
| Earnings Per Share (EPS ₹) | 15.31 | 15.31 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 11 | 11 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 443 | 443 ▲ 0.0% |
| Material Cost % of RevenueDerived | 41.96% | 41.96% |
| Employee Cost % of RevenueDerived | 8.08% | 8.08% |
| Other Cost % of RevenueDerived | 21.98% | 21.98% |
| Interest Coverage (x)Derived | 27.23x | 27.23x |
| Period | Mar 2026 | May 2026 | Trend |
|---|---|---|---|
| Revenue from Operations | 642 | 642 ▲ 0.0% | |
| Other Income | 29 | 29 ▲ 0.0% | |
| Total Income | 671 | 671 ▲ 0.0% | |
227 | 227 ▲ 0.0% | ||
| Gross ProfitDerived | 415 | 415 ▲ 0.0% | |
| Gross Margin %Derived | 64.61% | 64.61% | |
193 | 193 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 222 | 222 ▲ 0.0% | |
| OPM %Derived | 34.55% | 34.55% | |
22 | 22 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 228 | 228 ▲ 0.0% | |
54 | 54 ▲ 0.0% | ||
| Effective Tax %Derived | 23.58% | 23.58% | |
| Total Profit for Period | 174 | 174 ▲ 0.0% | |
| Less: Non-controlling Interests | 1 | 1 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 173 | 173 ▲ 0.0% | |
| Net Profit Margin %Derived | 26.92% | 26.92% | |
| Earnings Per Share (EPS ₹) | 15.31 | 15.31 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 11 | 11 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 443 | 443 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 41.96% | 41.96% | |
| Employee Cost % of RevenueDerived | 8.08% | 8.08% | |
| Other Cost % of RevenueDerived | 21.98% | 21.98% | |
| Interest Coverage (x)Derived | 27.23x | 27.23x |
SUDEEP PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at SUDEEP PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
SUDEEP PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for SUDEEP PHARMA.
Our AI distills the core fundamental drivers supporting SUDEEP PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 80 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 14% would indicate weaker capital compounding.
SUDEEP PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SUDEEP PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
SUDEEP PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for SUDEEP PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
SUDEEP PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for SUDEEP PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in SUDEEP PHARMA stood at 45.5% of traded volume, against a 20-day average of 54.6%.
SUDEEP PHARMA announcements: results, concalls, ratings, M&A.
Filings SUDEEP PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
SUDEEP PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 61 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Sudeep Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Change in Management
Sudeep Pharma Limited has informed the Exchange about change in Management
Trading Window
Sudeep Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Sudeep Pharma Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
SUDEEP PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue SUDEEP PHARMA has declared, sequenced by announce and record date.
SUDEEP PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About SUDEEP PHARMA: business, sector, key facts.
What SUDEEP PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
SUDEEP PHARMA is a listed Indian equity, listed as NSE: SUDEEPPHRM, BSE: 544619.
SUDEEP PHARMA
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about SUDEEP PHARMA (SUDEEPPHRM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of SUDEEP PHARMA (SUDEEPPHRM)?
The current share price of SUDEEP PHARMA (SUDEEPPHRM) is ₹1,003.30. Today, the stock has gained by ₹2.60 (0.26%), trading in a range of ₹964.70 to ₹1,016.80. The stock opened at ₹999.00 with a trading volume of 1,94,805 shares.
02Is SUDEEP PHARMA stock a good investment for long-term?
SUDEEP PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,289.22 Cr., P/E ratio of 61.74, ROE of 19.41%, and ROCE of 17.66%. The dividend yield stands at 0.15%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of SUDEEP PHARMA stock?
The 52-week high price of SUDEEP PHARMA (SUDEEPPHRM) is ₹1,378.00, while the 52-week low is ₹524.05. Currently trading at ₹1,003.30, the stock is 91.45% above its 52-week low and 27.19% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy SUDEEP PHARMA stock at the current price?
Whether to buy SUDEEP PHARMA stock at ₹1,003.30 depends on multiple factors. The stock is currently trading with a P/E ratio of 61.74 and P/B ratio of 12.78. Today's performance shows a gain of 0.26%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of SUDEEP PHARMA and when is the next dividend?
SUDEEP PHARMA offers a dividend yield of 0.15%, which means for every ₹100 invested at the current price of ₹1,003.30, you can expect to receive approximately ₹0.15 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of SUDEEP PHARMA?
SUDEEP PHARMA's key financial metrics include: P/E Ratio: 61.74, P/B Ratio: 12.78, ROE: 19.41%, ROCE: 17.66%, Dividend Yield: 0.15%, EPS: ₹3.59, Book Value: ₹79.51, and Debt-to-Equity: 0.17. The company's market cap stands at ₹11,289.22 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is SUDEEP PHARMA stock performing today in the market?
SUDEEP PHARMA stock opened at ₹999.00 and is currently trading at ₹1,003.30, showing a gain of ₹2.60 (0.26%). The intraday high is ₹1,016.80 and low is ₹964.70. The trading volume stands at 1,94,805 shares, indicating moderate market participation today.
08What is the P/E ratio of SUDEEP PHARMA and what does it indicate?
SUDEEP PHARMA has a Price-to-Earnings (P/E) ratio of 61.74, which means investors are willing to pay 61.74 for every ₹1 of earnings. With an EPS of ₹3.59, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about SUDEEP PHARMA (SUDEEPPHRM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.